# ARA-290 (Cibinetide) Research Guide 2026: Innate Repair Receptor Peptide
For Research Use Only. Not for human use. Not for clinical or veterinary diagnostic use.
Introduction
ARA-290, also known as cibinetide, is an investigational 11-amino-acid peptide derived from the structure of erythropoietin (EPO) that has generated significant research interest for its anti-inflammatory and tissue-protective properties. Unlike full erythropoietin, ARA-290 selectively activates the innate repair receptor—a specific signaling complex—to reduce inflammation and support nerve repair without stimulating red blood cell production.
The compound emerged from decades of research into EPO's non-hematopoietic (non-blood-forming) mechanisms. Pharmaceutical interest peaked following Phase 2 clinical trials demonstrating regrowth of small nerve fibers in patients with neuropathic pain related to sarcoidosis and other inflammatory conditions. As of 2026, ARA-290 remains investigational and is not FDA-approved for any indication, though published research continues to explore its potential across multiple tissue types.
Mechanism of Action
Innate Repair Receptor (IRR)
ARA-290's primary mechanism centers on activation of the innate repair receptor, a signaling complex composed of:
- •Erythropoietin receptor (EPOR) — the classical EPO-binding subunit
- •Beta-common receptor (CD131) — a shared signaling partner in the cytokine receptor superfamily
This heterodimeric complex is distinct from the full-length EPO receptor that drives red blood cell proliferation, allowing ARA-290 to trigger tissue-protective signaling without erythropoietic (blood cell-stimulating) side effects.
Downstream Signaling Pathways
Activation of the innate repair receptor by ARA-290 initiates anti-inflammatory and cytoprotective cascades:
- •JAK/STAT3 signaling — Activates pro-survival and anti-inflammatory gene expression in neurons and immune cells
- •Microglia modulation — Reduces pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6) and promotes shift toward reparative phenotypes
- •Neurotrophic support — Upregulates nerve growth factor (NGF) signaling and supports axonal regeneration
- •Oxidative stress reduction — Decreases reactive oxygen species (ROS) production in nerve tissue and endothelial cells
Research Applications
Neuropathic Pain & Nerve Regeneration
The strongest published evidence for ARA-290 comes from Phase 2 trials in neuropathic pain associated with sarcoidosis and other inflammatory conditions. These studies demonstrated:
- •Small nerve fiber regeneration — Objective increase in intraepidermal nerve fiber (IENF) density
- •Pain reduction — Significant decreases in neuropathic pain scores
- •Microglia suppression — Reduced inflammatory markers
Researchers attribute these effects to ARA-290's ability to dampen aberrant neuroinflammation—the chronic activation of microglia that perpetuates neuropathic pain even after the initial injury has resolved.
Retinal Protection & Diabetic Eye Disease
ARA-290's tissue-protective mechanisms have also been explored in ocular research. Phase 2 trials evaluated subcutaneous ARA-290 in patients with diabetic macular edema, a leading cause of vision loss. The mechanism involves:
- •Reduction of retinal microglial activation and VEGF-mediated permeability
- •Direct protection of retinal endothelial cells from hyperglycemic stress
- •Stabilization of the blood-retinal barrier
Pharmacology & Administration
Source & Reconstitution
ARA-290 is typically supplied as a lyophilized (freeze-dried) powder in vials ranging from 2 mg to 10 mg per vial. Reconstitution follows standard peptide protocols:
- •Diluent: Bacteriostatic water (BAC water) or sterile saline
- •Concentration: Generally reconstituted to 1–2 mg/mL for research use
- •Storage (powder): Room temperature, protected from light (typically stable 24+ months unopened)
- •Storage (reconstituted): Refrigeration at 2–8°C; typically used within 2–4 weeks
Administration Routes & Research Protocols
Published Phase 2 trials used subcutaneous (SubQ) injection, which remains the primary route in research:
- •Typical dose range: 1–4 mg per administration
- •Frequency: Once daily or every other day, depending on protocol
- •Route: Subcutaneous injection (abdomen, thigh, or upper arm)
- •Needle gauge: 25–29G insulin-style needles
Half-Life & Pharmacokinetics
- •Plasma half-life: Approximately 5–7 hours (similar to recombinant EPO)
- •Peak concentration (Cmax): Reached 2–4 hours post-injection
- •Clearance: Predominantly renal; no major hepatic metabolism
Quality, Sourcing & Purity
When sourcing ARA-290 for research:
1. Purity verification — Request certificates of analysis (CoA) documenting peptide purity ≥95% by HPLC
2. Endotoxin testing — Verify endotoxin levels <1 EU/mg (particularly important for systemic research)
3. Sterility & microbiology — Check for bacterial and fungal contamination testing
4. Mass spectrometry confirmation — Molecular weight verification (ARA-290 MW ~1,300 Da)
5. Supplier reputation — Source from specialized research peptide suppliers with traceability
Cross-reference suppliers available on the Peptides.SO platform for comparative pricing and quality ratings.
Regulatory Status (2026)
ARA-290 is not FDA-approved for any human indication as of September 2026. The compound's development history includes:
- •Araim Pharmaceuticals — Original developer; pursued IND applications for neuropathic pain and diabetic macular edema
- •IND closure — Araim ceased operations; no active U.S. IND (Investigational New Drug) sponsor as of 2026
- •Global status — Not approved in EU, Japan, or other major markets
- •Research access — Available through research chemical suppliers for laboratory and animal model research
RUO Status & Applicable Disclaimers
ARA-290 is an investigational peptide intended for research use only:
- •Not for human consumption — Clinical efficacy and safety remain incompletely characterized
- •Not for veterinary use — Outside the scope of approved veterinary medicines
- •Research use only — Subject to institutional review and compliance with laboratory research guidelines
Comparison with Related Peptides
| Peptide | Source | Mechanism | Status |
|---|---|---|---|
| ARA-290 | EPO-derived | Innate repair receptor | Investigational |
| Sermorelin | GHRH analog | GH secretion | FDA-approved |
| BPC-157 | Gut-derived | GlyProGlu tripeptide | Research-use |
| GHK-Cu | Collagen-derived | Collagen remodeling | Research-use |
Research & References
Key published evidence supporting ARA-290 research includes work from Stealth BioTherapeutics and academic collaborators on innate repair receptor mechanisms and clinical data.
Conclusion
ARA-290 (cibinetide) represents a novel approach to targeting inflammation and supporting tissue repair through selective innate repair receptor activation. Its Phase 2 data in neuropathic pain and diabetic retinal disease, combined with its favorable selectivity profile (non-erythropoietic), position it as a compelling research target for conditions driven by neuroinflammation. Ongoing preclinical studies continue to explore applications in cardiovascular and renal protection.
---
Related Guides: